MacroGenics (NASDAQ: MGNX) Navigates Strategic Transformation and Q1 Financials

Font: Financial Modeling Prep  • May 14, 2026

• MacroGenics (NASDAQ: MGNX) is strategically transforming its business by divesting manufacturing operations to focus on core drug development, aiming to extend its cash runway through 2028.
• The company reported a Q1 earnings per share (EPS) of -$0.58, slightly missing estimates, but posted strong revenues of $20.78 million, significantly surpassing expectations.
• Despite a negative Price-to-Earnings (P/E) ratio of -3.75, MacroGenics demonstrates adequate liquidity with a current ratio of 1.90 and a Price-to-Sales ratio of 1.68.

MacroGenics (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company that focuses on discovering and developing new medicines. The company is undergoing a significant business transformation. As highlighted by GlobeNewswire, MacroGenics is selling its manufacturing operations to Bora Pharmaceuticals to concentrate on its core drug development activities. This move is expected to extend its cash runway through 2028.

On May 14, 2026, MacroGenics reported its first-quarter financial results. The company announced an earnings per share (EPS) of -$0.58. This figure represents the portion of a company's profit allocated to each share of stock. The result slightly missed the consensus analyst estimate of -$0.57 per share.

Despite the earnings miss, MacroGenics' performance shows improvement from the same period a year ago, when it reported a loss of $0.65 per share. MacroGenics also posted strong revenues of $20.78 million for the quarter. This amount significantly surpassed the estimated $15.24 million and the $13.19 million recorded in the year-ago quarter.

Looking at its valuation, MacroGenics has a negative Price-to-Earnings (P/E) ratio of -3.75. A negative P/E ratio indicates that the company has not been profitable over the last twelve months. However, its Price-to-Sales ratio, which compares the stock price to revenues, stands at 1.68.

The company's financial health shows a Debt-to-Equity ratio of 1.72, which measures its financial leverage by comparing total debt to shareholder equity. MacroGenics also has a current ratio of 1.90. This suggests it has enough short-term assets to meet its short-term obligations, indicating adequate liquidity.